Medicine Recommendations

NICE TA744 - Upadacitinib for treating moderate rheumatoid arthritis

MHRA Drug Safety Update, 26 April 2023

JAK Inhibitors MHRA Drug Safety Update

Upadacitinib for previously treated moderately to severely active Crohn’s disease

NICE TA 905 - Upadacitinib for previously treated moderately to severely active Crohn’s disease

Ustekinumab for treating moderately to severely active ulcerative colitis (TA 633)

Treatment of active psoriatic arthritis - rapid review of TA 313 (NICE TA340)

NICE TA 340 - Ustekinumab for treating active psoriatic arthritis (rapid review of technology appraisal guidance 313) 

MHRA Drug Safety Update - Ustekinumab (Stelara): risk of exfoliative dermatitis

Moderate to severe plaque psoriasis (NICE TA180)

NICE TA180 - Ustekinumab for the treatment of adults with moderate to severe psoriasis

MHRA Drug Safety Update - Ustekinumab (Stelara): risk of exfoliative dermatitis

Moderately to severely active Crohn’s disease after previous treatment (NICE TA456)

NICE TA456 - Ustekinumab for moderately to severely active Crohn’s disease after previous treatment

For the management of foot ulcers in the diabetic population

Sexual pain-penetration disorder (SPPD) in combination with pychosexual therapy.

Manic episodes associated with bipolar disorder.

National Patient Safety Alert: Valproate: organisations to prepare for new regulatory measures for oversight of prescribing to new patients and existing female patients

MHRA Drug Safety Update - Valproate medicines (Epilim▼, Depakote▼): contraindicated in women and girls of childbearing potential unless conditions of Pregnancy Prevention Programme are met 

MHRA Drug Safety Update: Valproate use in men: as a precaution, men and their partners should use effective contraception

Erectile dysfunction

Smoking cessation (NICE TA123)

NICE TA123 - Varenicline for smoking cessation

Immunisation against herpes zoster

Use in high-risk patients for prevention of recurrence or upon recurrence of Crohn's Disease following surgery.

First, second and third-line treatment of moderately to severely active Crohn's disease after prior therapy (NICE TA352)

NICE TA 352 - Vedolizumab for treating moderately to severely active Crohn's disease after prior therapy

First, second and third-line treatment of moderately to severely active ulcerative colitis (NICE TA342)

NICE TA 342 - Vedolizumab for treating moderately to severely active ulcerative colitis

Prevention of recurrence of ulcerative colitis following surgery.

Crohn's disease
Ulcerative colitis

Depressive illness, generalised anxiety disorder (XL formulation only)

Symptoms of overactive bladder syndrome (NICE TA999)

NICE TA999 - Vibegron for treating symptoms of overactive bladder syndrome

Following a gastric bypass